Multi-compartment device containing human three-dimensional (3D) microtissues for toxicity testing
This dual-compartment liver co-culture system exposes target microtissue to metabolites, allowing for evaluating toxicity using a standard multi-well plate for high throughput analysis. Discovery scientists can rapidly select lead compounds with desirable metabolic profiles, while safety scientists can determine the safety of drugs, pesticides, and environmental chemicals. This platform is allometrically scalable, so it can mimic the natural size differences between healthy organs and, with the liver, produce sufficient quantities of metabolites. The device is simple to use and designed for immediate in vitro pathology assessment using confocal microscopy, transcriptomics, and proteomics.
1. A device comprising at least a first compartment and a second compartment, with a central permeable wall between the first compartment and the second compartment; the permeable wall being a cell barrier that is impermeable to cells but permeable to small molecules, biomolecules, and proteins including hormones, without requiring a use of an impermeable wall with one or more capillary openings;
(a) wherein the first compartment is in an opening in a shape of a toroid, surrounding the central permeable wall acting as a molecule-permeable barrier, with a first floor and an outer wall adapted for containing three-dimensional (3D) metabolizing and hormone-producing microtissues, and wherein the first compartment can be seeded with cells from a cell population and the seeded cells will grow into one or more 3D microtissues surrounding the central cell barrier or permeable wall; the first compartment operative to accept a test compound, and the one or more 3D microtissues being capable of metabolizing the test compound;
(b) wherein the central permeable wall includes a hollow center with a second floor forming the second compartment surrounded by the central permeable wall;
(c) wherein the second compartment is adapted for containing cells of a selected target cell population that do not cross over to the first compartment, and wherein the second compartment can be seeded with cells, cells in a gel, or cells in a liquid from a selected target cell population and said cells are operative to grow into one or more target cells in a form of one or more microtissues, a two-dimensional (2D) attached monolayer of cells, and/or into a 3D spheroid; and
(d) whereupon if the 3D microtissue(s) metabolizes the test compound, metabolites and hormones resulting from one or more effects of the test compound on the 3D microtissues in the first compartment can passively diffuse through the central permeable wall to the one or more target cells in the second compartment and from the second compartment into the first compartment.
2. The device of claim 1 , wherein the 3D microtissue in the first compartment is allometrically scaled to deliver metabolites and to the microtissue in the second compartment.
3. The device of claim 1 , wherein the wall between the first compartment and the second compartment comprise a non-adhesive hydrogel having sufficient porosity to permit metabolites and hormones from the 3D microtissues to diffuse from the first compartment to the second compartment and from the second compartment to the first compartment.
4. The device of claim 1 , wherein
(a) the first compartment contains 3D microtissues in a culture medium; and
(b) the second compartment contains the selected target cell population in a culture medium.
5. The device of claim 1 , wherein the device fits in one well of a standard multi-well plate.
6. A method for measuring the toxicity of a test compound, comprising the steps of
(a) obtaining the device of claim 1 ;
(b) adding the test compound to the first compartment, under conditions so the first compartment contains 3D microtissues in a culture medium;
(c) permitting the metabolites from the 3D microtissues in the first compartment to diffuse to the second compartment, under conditions, so the second compartment contains microtissues of the selected target cell population in a culture medium;
(d) measuring the effect of the metabolites from the 3D microtissues in the first compartment on the microtissues of the selected target cell population, using an assay that measures a morphological, molecular, or functional endpoint, wherein the endpoint provides a safety assessment of the test compound.
7. The method of claim 6 , wherein the assay is amenable to a high throughput workflow.